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Intrinsic or acquired resistance to chemotherapeutic agents is a common phenomenon
and a major challenge in the treatment of cancer patients. Chemoresistance is defined
by a complex network of factors including multi-drug resistance proteins, reduced cellular
uptake of the drug, enhanced DNA repair, intracellular drug inactivation, and evasion of
apoptosis. Pre-clinical models have demonstrated that many chemotherapy drugs, such
as platinum-based agents, antracyclines, and taxanes, promote the activation of the NF-
κB pathway. NF-κB is a key transcription factor, playing a role in the development and
progression of cancer and chemoresistance through the activation of a multitude of medi-
ators including anti-apoptotic genes. Consequently, NF-κB has emerged as a promising
anti-cancer target. Here, we describe the role of NF-κB in cancer and in the development
of resistance, particularly cisplatin. Additionally, the potential benefits and disadvantages
of targeting NF-κB signaling by pharmacological intervention will be addressed.
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INTRODUCTION
Platinum-based anti-cancer drugs, such as cisplatin, play a crucial
role in the treatment of cancer. The cytotoxic effect of these drugs
relies on their ability to induce DNA damage. However, intrinsic
or acquired resistance to chemotherapy often critically limits the
efficacy and outcome of treatment. Much progress has been made
delineating the mechanisms of cellular resistance, which include
reduced intracellular accumulation of the drug, increased DNA
repair and altered oncogene and regulatory protein expression. In
addition, increased expression of anti-apoptotic genes and muta-
tions in the intrinsic apoptotic pathway contribute to impaired
DNA damage detection and apoptosis induction (Kartalou and
Essigmann, 2001). Recently, Nuclear Factor-kappa B (NF-κB) has
been identified as a key player in resistance mechanisms (Thevenod
et al., 2000; Bottero et al., 2001; Braeuer et al., 2006).
Nuclear Factor-kappa B (NF-κB) is a tightly regulated tran-
scription factor, composed of homo or heterodimers from a pool
of five REL proteins: NF-κB1(p50), NF-κB2 (p52), RelA (p65),
RelB, and c-Rel (Rel). However, their biological effects are cell
type dependant, mediating diverse physiological processes. In
un-stimulated cells, NF-κB is sequestered within the cytoplasm,
bound to its regulatory protein, inhibitor of NF-κB (IκB). NF-
κB activation is driven by the phosphorylation of IκB, resulting
in the dissociation of the NF-κB:IκB complex. Consequently,
exposing the nuclear localization sequence of NF-κB, thus induc-
ing its translocation into the nucleus (Ghosh et al., 1998). After
homo/heterodimer formation, NF-κB binds to specific promoter
sequences (κB sites) contained within many genes, which play
important roles in cellular growth and apoptosis (Pahl, 1999).
Traditionally the activation of NF-κB occurs through two inde-
pendent signaling pathways: in the canonical pathway, binding
of a ligand to a cell surface receptor, such as a member of the
toll-like-receptor (TLR) superfamily, leads to the recruitment
of adaptors (such as TRAF) to the cytoplasmic domain. TRAF
recruits and activates the IKK complex, containing the IKKβ or
IKKα protein and the scaffold protein, NF-κB essential modulator
(NEMO). IKK phosphorylates two serine residues (ser32/ser36),
in the IκBα regulatory domain resulting in dissociation of the
NFκB:IκB complex. The non-canonical pathway is activated in
response to non-inflammatory stimuli, such as BAFFR induced
B-cell maturation (Crowley et al., 2005). Non-canonical signaling
is mediated via IKKα independent of NEMO, but requires NF-κB-
inducing kinase (NIK) (Li and Verma, 2002). Recently, an alternate
pathway of NF-κB activation has also been described, which does
not require IKK. For example, the activation of NF-κB by UV light
occurs via casein kinase 2 and subsequent calpain-dependent IκB
degradation (Figure 1) (Kato et al., 2003).
NF-κB AND CANCER
NF-κB and its target genes have been implicated as mediators in
all of the hallmarks of cancer (Pahl, 1999; Hanahan and Weinberg,
2011). Constitutive activation of NF-κB has been demonstrated
in lung (Tew et al., 2008), breast (Chua et al., 2007), lymphoma
(Zou et al., 2007), and leukemia (Vilimas et al., 2007) cell lines.
Elevated NF-κB levels correlate with poor prognostic outcome in
ovarian cancer (Annunziata et al., 2010) and glioblastoma (Brown
and Law, 2006). The inhibition of NF-κB signaling or NF-κB gene
knockout, has been shown to mediate anti-tumor responses (Li
et al., 2005a; Meylan et al., 2009).
NF-κB AND CHEMOTHERAPEUTIC RESISTANCE
In addition to its role in cancer cell survival (Li et al., 2005a),
activated NF-κB has also been identified as a key mecha-
nism of cisplatin resistance. NF-κB activity inversely correlated
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FIGURE 1 | Activation of NF-κB can be described by distinct pathways,
according to the mechanism of IκB degradation. Canonical signaling,
initiated by toll-like-receptor (TLR) ligation, is dependent on the IKK complex
containing NF-κB essential modulator (NEMO) and IKKα/IKKβ. Non-canonical
signaling occurs in response to ligation of a subset of tumor-necrosis factor
receptor (TNFs) members, is dependent on the NF-κB-inducing kinase (NIK),
which activates proteolytic processing of p100 by IKKα. NF- κB activation can
also occur through a IKK-independent mechanism, induced by DNA damage
detection, involving the serine threonine kinase casein kinase 2 (CK2), which
activates the IκB targeting cysteine protease calpain.
with cellular sensitivity to chemotherapy in carcinoma cell lines
(Chuang et al., 2002). Furthermore, long term treatment of a panel
of lung cancer cell lines, with increasing doses of cisplatin, pro-
duced cell lines resistant to cisplatin mediated cell death (Barr et al.,
2013). These resistant cells show increased expression of NF-κB,
compared to their matched cisplatin sensitive parent, implicat-
ing NF-κB as a potential mediator of acquired cisplatin resistance
(unpublished data).
Nuclear proteins, isolated from prostate cancer cells treated
with cisplatin, had activated NF-κB levels greater than untreated
control cells, as measured by increased DNA binding activity.
This activity could be abrogated by transfection with p65 siRNA.
Cisplatin, therefore, enhanced the DNA binding activity of NF-
κB, through increased expression and activation of the protein,
thereby limiting its own potential efficacy. Treatment of cells with
genistein, an AKT-NF-κB inhibitor, abrogated the increased NF-
κB activity in murine models, sensitizing them to cisplatin induced
apoptosis (Li et al., 2005a).
NF-κB SIGNALING
Many cancer cells rely on oncogene addiction for maintenance of
their malignant phenotype (Weinstein, 2002). This over reliance
can dictate the choice of molecularly targeted therapies, as inhibi-
tion of these “addictive” pathways, such as the NF-κB pathway, can
sensitize cancer cells to apoptosis (Ariga et al., 2002). However, the
activation of NF-κB is inherently complex, given the multitude of
signaling pathways and crosstalk connections which can stimulate
it. It is therefore essential to identify cancer cell specific pathways,
to broaden our understanding of NF-κB signaling, thus allowing
for rational selection of suitable inhibitors.
Growth factor receptor stimulation
In response to extracellular signals, a number of growth factor
receptors can activate NF-κB via the PI3K/AKT pathway (Crowley
et al.,2005). Elevated expression of EGFR in ovarian,cervical,blad-
der,and esophageal cancer has been correlated with poor prognosis
in the clinical setting (Nicholson et al., 2001). Cisplatin has been
shown to possess EGF-like activity, as treatment of A549 cells with
cisplatin resulted in the phosphorylation of EGFR and the acti-
vation of the PI3K/AKT/NF-κB pathway. Therefore, in NSCLC
a potential explanation for cisplatin induced NF-κB expression
may occur through the stimulation of EGFR (Kuroda et al., 2010).
This data suggests that treatment with cisplatin may induce con-
stitutive activation of EGFR, and consequently cisplatin resistance
via NF-κB.
The PI3K/AKT pathway
The PI3K/AKT pathway responds to a milieu of intracellular and
extracellular signals via receptor tyrosine kinase (RTK) receptors.
AKT is a critical signaling molecule, which acts as a central hub
for many cell growth and survival pathway. Activating PI3K path-
way mutations are common in cancer and have been implicated
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in the development of cisplatin resistance. PI3K/AKT inhibitors
re-sensitize cells to treatment in many cancer types, including ovar-
ian (Non-aka et al., 2012). Primary acute myeloid leukemia cells,
with constitutive AKT activation, treated with the AKT inhibitor
LY294002, showed a reduction in both p-AKT, and NF-κB levels
resulting in apoptosis. In this instance NF-κB activation is occur-
ring in an AKT-dependent manner. Therefore, the AKT-NF-kB
pathway may represent a viable mechanism for overactive PI3-
kinase to promote resistance to cytotoxic agents (Grandage et al.,
2005).
AKT mediated NF-κB activation requires the effector mole-
cule mTOR, which forms the catalytic subunit of two molec-
ular signaling complexes; mTOR complex 1 (mTORC1) and 2
(mTORC2). mTORC1 is associated with endosomal membranes,
where it promotes the translation of NF-κB regulated mRNAs,
such as Bcl-2, Bcl-xL, and cyclin D, through the effector 4E-binding
protein 1 (4E-BP1) (De Benedetti and Graff, 2004). Chronic acti-
vation of mTORC1 is frequent in cancer (Meric-Bernstam and
Gonzalez-Angulo, 2009). AKT dependant mTORC1 activation
occurs through phosphorylation of the tuberous sclerosis complex
(TSC) and subsequent activation of the mTORC1 regulator, Rheb
(Inoki et al., 2002). Rapamycin induced inhibition of mTORC1
suppresses breast cancer induction in mouse models (Namba et al.,
2006), whereas incremental Rheb induction promotes metastasis
and tumor progression (Lu et al., 2010). Therefore, PI3K/AKT-
dependent mTORC1 activation contributes to cancer promotion
and chemoresistance possibly through the translation of NF-κB
target genes.
In contrast,mTORC2 may be activated through ribosome bind-
ing and once activated phosphorylates AKT ser473 (Sarbassov
et al., 2005; Zinzalla et al., 2011). It’s role in cancer is not clear,
although it is required for PTEN loss-induced prostate cancer in
mice, suggesting a central role in PI3K-dependant carcinogene-
sis (Guertin and Sabatini, 2009). The allosteric mTOR inhibitor,
rapamycin, does not inhibit mTORC2, offering an explanation for
the failure of rapamycin in PI3K-hyperactivated cancer (Clough-
esy et al., 2008). PI3K signaling is hyperactivated in 90% of
glioblastomas, and is associated with EGFRvIII, a mutant acti-
vated EGFR, and mTORC2 activation. In addition, EGFRvIII
mutants express elevated NF-κB activity and resistance to DNA
damaging agents. These mutants are dependent on mTORC2
expression but not AKT or mTORC1 signaling (Tanaka et al.,
2011). mTORC2 represents a mechanism of NF-κB activation
and subsequent chemotherapeutic resistance in EGFR mutated
cancers.
The MAP kinase/ERK pathway
The RAS-Mitogen activated Protein Kinase (MAPK) pathway is
integral to transducing extracellular signals, including cytokines
and growth factors (Enzler et al., 2011). Central to this path-
way is the activation of RAS by the guanine exchange factor son
of sevenless (SOS). The activated GTP-bound RAS activates the
serine/threonine kinase, RAF, which in turn activates MAPKs,
including extracellular signal regulated kinase (ERK). ERK 1/2
translocate to the nucleus where they activate the Jun/Fos family
of transcription factors. Due to its central role in cellular prolifer-
ation it is not surprising that the SOS-Ras-Raf-MAPK cascade is
often mutated in cancer, with RAS mutations found in ∼45% of
colon and∼90% of pancreatic cancers (Katz et al., 2007).
Cisplatin induces the persistent activation of the apoptotic
MAPK and c-jun N-terminal kinase (JNK) pathways. The apop-
totic nature of this pathway may be through MAP2K and MEKK1,
which activate JNK. This pathway may also activate NF-κB, result-
ing in differential apoptotic signaling. Through this mechanism
MAPK can drive the activation of NF-κB in response to cisplatin
treatment (Sanchez-Perez et al., 2002). This means that inactivat-
ing mutations in the JNK pathway could lead to signaling only
via the NF-κB pathway in response to cisplatin treatment, thereby
providing a potential mechanism of resistance.
Raf kinase inhibitor protein (RKIP) is a metastasis suppres-
sor/immunosurveillance cancer gene, which acts as a negative
regulator of both the MAPK cascade, initiated by Raf-1 (Yeung
et al., 1999), and NF-κB activation, through the negative reg-
ulation of IκB (Yeung et al., 2001). RKIP loss or depletion has
been correlated with metastasis and chemotherapeutic resistance
in solid tumors (Chatterjee et al., 2004). In prostate cancer, RKIP
is regulated by the transcriptional repressor Snail. Transcription
of Snail is partly regulated by NF-κB (Julien et al., 2007) and is a
key modulator in metastasis (Beach et al., 2008). Prostate cancer
cells which exhibit constitutive NF-κB activation express increased
levels of Snail, which in turn inhibits RKIP expression protecting
cells from chemotherapy induced apoptosis (Baritaki et al., 2009).
Inhibition of NF-κB, by DHMEQ, decreases the expression of Snail
and Bcl-xL leading to elevated expression levels of RKIP, thereby
re-sensitizing cells to chemotherapy (Baritaki et al., 2009).
Janus Kinase/Signal Transducers and Activators of Transcription
pathway
Upon binding to their cognate receptors, receptor associated Janus
Kinases (JAKs) phosphorylate ligand-bound receptors resulting in
the recruitment and activation of Signal Transducers and Activa-
tors of Transcription (STATs) (Darnell et al., 1994). Phosphory-
lated STATs form homodimers, localize to the nucleus, and regulate
genes associated with apoptosis and proliferation (Darnell, 2002).
Persistent activation of STATs has been shown in primary tumors
and cancer cell lines, where it is believed to contribute to onco-
genesis (Bromberg, 2002). It is thought that STAT3 can bind to
and cause the dissociation of the NF-κB:IκB complex (Yang et al.,
2007). This can prolong NF-κB retention in the nucleus by altering
its acetylation status via interactions with p300 (Lee et al., 2009).
STAT3 can therefore promote NF-κB activation even in the absence
of IKK signaling. Silencing of STAT3 reduced Bcl-xL expression, a
NF-κB target gene, re-sensitizing A549 cells to cisplatin (Kulesza
et al., 2013).
ONCOGENES AND NF-κB
p53 is a tumor suppressor protein activated upon cellular stress,
such as DNA damage. Once activated it binds DNA, where it mod-
ulates the expression of genes associated with DNA repair and
apoptosis (MacFarlane et al., 1996). p53 is therefore an impor-
tant mediator of cisplatin induced cell death. Interestingly, NF-κB
can bind the p53 promoter region inducing its transcription (Kim
et al., 2002), to form a negative feedback loop. Loss of function p53
mutations are a common occurrence in cancer (Greenblatt et al.,
www.frontiersin.org May 2013 | Volume 3 | Article 120 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Godwin et al. Targeting NFkB to overcome chemoresistance
1994) and the failure of this control mechanism could potentially
induce constitutive activation of the NF-κB pathway. A panel of
p53 mutated NSCLC cell lines, which were resistant to cisplatin,
became sensitive to treatment upon transfection with the p53 wild
type gene (Lai et al., 2000). Thus, p53 gene status may play a
significant role in the development of cisplatin resistant NSCLC.
The impact of a p53 mutation in NSCLC can be influenced
by the presence of additional oncogenic mutations. The signaling
protein, Ras, acts as molecular switch and once activated it propa-
gates downstream signaling pathways leading to NF-κB activation
via the IKK tank-binding kinase 1 (TBK1) (Barbie et al., 2009).
NF-κB activation by oncogenic Ras (KRAS) is implicated in lung
carcinogenesis (Barbie et al., 2009). KRAS mutations are found
in 20–30% of NSCLC cases, while inactivating mutations of p53
occur at a rate of approximately 50% (Herbst et al., 2008). Fur-
thermore, both mutations when occurring simultaneously lead to
the development of lung adenocarcinoma in mouse models, which
may be as a result of increased NFκB activity (Meylan et al., 2009).
Cisplatin induced apoptosis is likely to be mediated, at least in
part, by the induction of p53 in response to DNA damage. Conse-
quently, resistance to cisplatin in some cancers may be mediated
through KRAS mediated NF-κB activation.
NF-κB AND DNA REPAIR
Elimination of DNA damage, by cellular repair mechanisms or
destruction of the cell via apoptosis, is essential for the mainte-
nance of genome integrity and disease prevention. It is known that
the threshold for the induction of apoptosis is lower in cancer cells
in response to DNA damage compared with their normal coun-
terparts (Evan and Vousden, 2001; Enzler et al., 2011). Platinum-
based drugs induce apoptosis through DNA adduct formation
(Chaney et al., 2004). In mouse models, it has been shown that cis-
platin resistant cancer cells repair DNA adducts more efficiently,
compared with sensitive cells (Oliver et al., 2010). Nucleotide exci-
sion repair (NER), a major DNA repair pathway, repairs bulk DNA
damaged by environmental factors and chemotherapy (Friedberg
et al., 2006). The NER rate-limiting step is affected by the protein
products of the genes ERCC1 and XPAC. Up-regulated expression
of these genes has been correlated with increased drug resistance
in ovarian cancer (Dabholkar et al., 1994).
In a study of the role of Bcl-xL in NER-facilitated protection
against cisplatin, it was demonstrated that NER was required
for cisplatin induced NF-κB translocation. The exact mecha-
nism through which NER activates NF-κB is unknown, but is
understood to be dependent on the ataxia telangiectasia mutated
(ATM) protein (Wuerzberger-Davis et al., 2007). The ATM-NF-
κB pathway is believed to be negatively regulated by ATM and
rad-3-related (ATR) kinase. ATR has been shown to repress NF-
κB activation in response to replicative stress, by competitively
binding to NEMO (Wu and Miyamoto, 2008). Consequently cells
with high levels of ATR activity show decreased NF-κB levels and
increased apoptosis in response to cisplatin (Lomonaco et al.,
2009).
NF-κB TARGET GENES AND APOPTOSIS
NF-κB target genes play an important role in the regulation of
many of the pathways involved in the hallmarks of cancer. Genes
regulated by NF-κB include those that are associated with inflam-
mation (TNF, IL-6, and ICAM), cell survival (cIAP1/2, Bcl-2, and
Bcl-xL), proliferation (CDK2), tumor progression (COX2), angio-
genesis (VEGF), and also cell death (Fas and FasL) (Pahl, 1999).
Apoptosis can be initiated by signals which occur outside or within
the cell. These signals may promote cell survival, such as growth
factor stimulation, or induce apoptosis, e.g., Tumor-necrosis factor
(TNF). The apoptotic pathway is described through two distinct
mechanisms; loss of mitochondrial function and death receptor
signaling through the activation of the caspase cascade. It is the fine
balance of these antagonistic signals which ultimately determines
cell fate.
Mitochondrial dysregulation
The mitochondrial pathway of caspase activation is controlled by
the Bcl-2 family proteins, which act by modulating the release of
caspase activators from mitochondria (Estaquier et al., 2012). In a
prostate cancer cell line, PC3, the levels of anti-apoptotic signaling
proteins Bcl-2, Bcl-xL, and survivin were decreased in response
to the NF-κB inhibitor genistein. The decrease in expression of
these proteins occurred in association with the up-regulation of
p21waf1, a pro-apoptotic protein and cell cycle inhibitor. Genistein
re-sensitized resistant cells to docetaxel and cisplatin mediated
apoptosis (Li et al., 2005a). Similarly in the aggressive cisplatin
resistant cervical cancer cell line, SKOV3.ip1, inhibition of NF-κB
led to increased expression of Bid and decreased Bcl-2 and Bcl-xL
levels. This shift in expression of pro- and anti-apoptotic proteins
was reflected in the increased sensitivity of these cells to cisplatin
treatment (Yang et al., 2011). Apoptotic deregulation may rep-
resent an important mechanism through which NF-κB mediates
resistance.
Death receptor signaling
Members of the TNF receptor (TNFR) family and their cor-
responding ligands are crucial regulators of various cellular
processes. A number of TNFRs, including Fas and TRAIL, are
potent activators of the apoptotic caspase cascade through adap-
tor molecules such as FADD (Ashkenazi and Dixit, 1998). Due to
their role in the regulation of apoptosis they are often referred to as
death receptors (DRs). Cell death induced by these DRs is tightly
regulated by NF-κB target genes, including inhibitor of apoptosis
proteins (IAPs), TRAF-1/2 (Wang et al., 1998), and Bcl-2 proteins
(Wang et al., 1999). However, it has been shown that ectopic over-
expression of these genes affords only partial protection from DR
mediated apoptosis (Wang et al., 1999). More recently, a potent
inhibitor of DR signaling has been identified, called c-FLIP.
Micheau et al. (1999) first alluded to the role of c-FLIP in
chemoresistance in a study which demonstrated that the inhibition
of the FADD-caspase 8 pathway resulted in a decrease in tumor
cell sensitivity to drug-induced apoptosis. In a study to identify
novel pro-apoptotic proteins up-regulated by NF-κB-inducing lig-
ands (CD40, IL-1, and TNF), c-FLIP expression was found to
be increased at both mRNA and protein level. Analysis of Jurkat
cell lines, including an IκB over-expressing and NEMO deficient
mutant, treated with the NF-κB-inducing ligand P/I, showed abro-
gated c-FLIP expression compared to wild type control, indicating
c-FLIP expression was mediated by NF-κB (Kreuz et al., 2001).
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The murine B-cell line A20, susceptible to Fas mediated apoptosis,
was protected from apoptosis through B-cell receptor (CD40) sig-
naling, which is known to activate NF-κB. Pre-treatment of B-cells
with CD40 increased c-FLIP expression, mediating resistance to a
subsequent challenge with FasL. Conversely, dendritic cells resis-
tant to FasL could be sensitized to apoptosis by pre-treating with
cycloheximide. Cycloheximide prevents proteosomal degradation
of IκB, thereby preventing NF-κB activation and subsequent c-
FLIP expression (Micheau et al., 2001). Similarly, it was shown that
cisplatin-selected cervix carcinoma HeLa cell lines induced less
apoptosis in response to treatment with cisplatin or Fas-activating
antibody, than parental cells. Negative regulator of apoptosis c-
FLIP, but not Bcl-2, Bcl-xL, or IAPs, was found to be higher in
resistant cells. Treatment with c-FLIP anti-sense oligonucleotides
promotes cisplatin and Fas-antibody-induced apoptosis to a much
greater degree in resistant cells (Kamarajan et al., 2003). The
cancer associated gene (CAGE) regulates expression of epithelial-
mesenchymal transition (EMT)-related proteins through ERK,
AKT, and NF-κB in mouse B16F10 melanoma cells. Snail and c-
FLIP mediate the effects of CAGE protecting cells against celastrol,
an anti-cancer agent (Kim et al., 2009).
In ovarian cancer cells the expression of c-FLIP, in chemosen-
sitive (OV2008) and chemoresistant (C13∗) cells treated with
cisplatin and/or transfected with c-FLIP siRNA or cDNA,was mea-
sured. Treatment with cisplatin significantly decreased c-FLIP lev-
els in sensitive but not resistance cell lines. In OV2008 cells, c-FLIP
over-expression attenuated apoptosis, while the down regulation
of c-FLIP in C13∗ cells increased cisplatin mediated apoptosis
(Abedini et al., 2004). Furthermore, in cisplatin sensitive (T24)
and resistant (T24R2) bladder cancer cell lines, cisplatin mediated
suppression of c-FLIP expression was correlated with sensitivity
(Lee et al., 2013). Downregulation of c-FLIP expression has been
shown to sensitize many cancer types to chemotherapy including
cervical adenocarcinoma (Luo et al., 2008), breast (Rogers et al.,
2007), colorectal (Longley et al., 2006), and prostate (Wilson et al.,
2008). Cisplatin mediated c-FLIP degradation has been proposed
to occur via p53 dependant ubiquitination and proteasomal degra-
dation of c-FLIP (Abedini et al., 2008). This indicates a possible
mechanism of cisplatin resistance whereby loss or dysregulation
of p53 results in the loss of cisplatin mediated c-FLIP degradation
and failure to induce apoptosis.
Caspase cascade
Inhibitor of apoptosis proteins are a family of potent apoptosis
inhibitors characterized by three baculoviral IAPs that bind to and
inhibit caspase activity (Fu et al., 2003). In colorectal cancers, the
X-linked IAP (XIAP) mRNA levels are significantly higher in pri-
mary cancer tissue compared with normal mucosa, and expression
was correlated with disease progression and metastasis (Takeuchi
et al., 2005). Furthermore, in the cisplatin resistant prostate cell
line, LNCaP, IAP expression increased with the extent of cisplatin
resistance (Nomura et al., 2005). In a study of TRAIL induced
apoptosis it was found that constitutive activation of NF-κB led
to increased XIAP expression and resistance to TRAIL mediated
cell death (Braeuer et al., 2006). Similarly in melanoma cell lines,
the inhibition of NF-κB resulted in decreased XIAP expression
and induction of apoptosis (Bush et al., 2001). Furthermore, in
melanoma cells depletion of endogenous XIAP promoted apopto-
sis and reduced clonogenicity of cancer cells treated with cisplatin
(Silke et al., 2005). In a clinical study of head and neck squa-
mous cell carcinoma, high XIAP levels correlated with increased
resistance to cisplatin and decreased survival (Yang et al., 2012).
The expression levels of XIAP represent an important factor
in determining cell fate in response to apoptotic signaling and
cisplatin.
PRO-APOPTOTIC ROLE OF NF-κB
Induction of NF-κB in response to chemotherapy often leads to a
dysregulated apoptotic response, which may mediate chemoresis-
tance. Consequently, much work has focused on the development
of targeted therapies that block the NF-κB pathway in order to
induce cell death. However, due to the complexity of NF-κB sig-
naling, both pro- and anti-tumourigenic activities may result (Lin
et al., 1999; reviewed in Pikarsky and Ben-Neriah, 2006). It is likely
that several factors including cell type, nature of stimulus and
chromatin modifications can confer pro or anti-apoptotic activ-
ities of NF-κB (Radhakrishnan and Kamalakaran, 2006; Barisic
et al., 2008).
The most simplistic mechanism by which NF-κB contributes to
apoptosis is through transcriptional regulation of apoptotic gene
targets. For example, the NF-κB mediated expression of TRAIL
in T-cell leukemia is essential for apoptosis (Rivera-Walsh et al.,
2001). The p65 subunit can bind the intronic region of genes
transcribing DR5 and DR4, thereby inducing pro-apoptotic sig-
naling (Ravi et al., 2001). Furthermore, inhibition of NF-κB by
sodium salicylate can rescue cells from apoptosis in response to
TRAIL (Rae et al., 2007). Another DR, Fas, has been implicated
in NF-κB mediated apoptosis in adenovirus infected hepatocytes
(Kuhnel et al., 2000) and in adenocarcinoma cells treated with
TNF-α (Kimura et al., 2003). In glioblastoma cell lines, NF-κB
exerts a pro-apoptotic function in TRAIL- or CD95-induced apop-
tosis, which can be reversed by over-expression of the dominant-
negative IκBα-super-repressor (IκBα-SR). Conversely, stimulation
of NF-κB, due to over-expression of constitutively active IKKβ,
significantly increases TRAIL- or CD95-mediated apoptosis. In
this instance it was found that NF-κB promotes the formation of
the TRAIL or CD95 death-inducing signaling complexes (DISCs)
through enhanced recruitment of FADD and caspase-8 to the
activated receptors (Jennewein et al., 2012).
Unlike other NF-κB family members, NF-κB2/p100 is found to
play a pro-apoptotic role, acting as both an activator of caspase-8
and as a IκB protein. The carboxyl terminus of p100 contains a
death-domain, which mediates recruitment to and formation of
DISCs. Tumor-derived p100 mutants often lack this domain, pro-
viding resistance from death receptor mediated apoptosis. HT1080
cells transfected with a p100 mutant containing only the death-
domain underwent apoptosis. This pathway to apoptosis was
found to be dependent on caspase-8 activation, as the caspase
inhibitor CrmA negated the pro-apoptotic effect (Wang et al.,
2002).
It has been shown in a p53-inducible cell line, Saos-2, that
induction of p53 results in NF-κB activation and subsequent apop-
tosis. Inhibition or loss of NF-κB activity, abrogated p53-induced
apoptosis, indicating that NF-κB is essential in p53-mediated cell
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death (Ryan et al., 2000). Similarly, in a study of murine fibroblasts,
NF-κB was shown to mediate p53 activation, thereby inducing
pro-apoptotic signaling (Fujioka et al., 2004). Not only can NF-
κB result in p53 expression but a novel transcriptional target of
NF-κB, polo-like kinase-3 (PlK3), was shown to phosphorylate
p53 thus increasing its half-life and potency (Li et al., 2005b). Ele-
vated expression of p65 alone can be sufficient for the induction
of cell death, for example in MCF7/ADR breast cancer and M14
melanoma cells (Ricca et al., 2001). In these examples it is clear
that NF-κB can play an important role in apoptotic signaling.
In the auditory cell line HEI-OCI, cisplatin induced both apop-
tosis and NF-κB signaling. Pre-treatment of HEI-OCI cells with
the NF-κB inhibitor, Bay 11-7085, completely abrogated the apop-
totic effects of cisplatin, indicating a pro-apoptotic role for NF-κB
in this cell line (Chung et al., 2008). Site specific phosphoryla-
tion leads to differential expression of NF-κB target gene subsets,
depending on the κB-response elements present at individual pro-
moters (Anrather et al., 2005). In support of this, p65 induced in
response to certain cytotoxic stimuli such as UV light and certain
chemotherapeutic drugs is distinct from that induced by TNF-
α. NF-κB induced in response to these stimuli is associated with
histone deacetylases (HDACs) to suppress transcription of sev-
eral anti-apoptotic genes, including Bcl-xL and XIAP (Campbell
et al., 2004). It is therefore conceivable that post translational
modifications of NF-κB subunits promotes differential responses
by regulating interactions with promoters of transcription, such
as histone acetyltransferases (HATs) and repressors, including
HDACs (Miyamoto, 2004).
Chromatin remodeling controls the access of translational
machinery and transcription factors to DNA, thereby affecting
gene expression. Changes in histone acetylation status of NF-κB
genes have been implicated in pro-apoptotic NF-κB signaling. In
HEK293 cells, NF-κB can mediate cell survival through the EGFR
but mediates apoptosis through Fas interactions (Gibson,2004). In
response to EGFR stimulation, NF-κB is recruited to both pro- and
anti-apoptotic genes. At pro-apoptotic genes, NF-κB is complexed
with HDACs causing transcriptional repression. In contrast, at
anti-apoptotic gene sites, NF-κB is complexed with HATs caus-
ing transcriptional activation (Graham and Gibson, 2005). It is
likely that several factors, including cell type, nature of stimu-
lus, and chromatin modifications confer the pro or anti-apoptotic
activities of NF-κB.
TARGETING NF-κB
A vast body of evidence exists to support the rationale of pursuing
novel therapies which modulate the NF-kB pathway. Several points
of therapeutic intervention have been proposed including IKK
activation, IκB degradation, and NF-κB DNA binding (Nakanishi
and Toi, 2005). However, due to its key role in a wide spectrum
of cellular processes and its regulatory complexity, concerns have
been raised over potential off-target effects and associated toxi-
cities. It is only by fully elucidating the multiple tiers of NF-κB
activation and its regulatory complexity in cancer that we can
begin to design and select appropriate targeted therapies. One of
the success stories in NF-κB targeting is the ubiquitin-proteasome
inhibitor bortezomib, approved for clinical use in newly diagnosed
and relapsed/refractory multiple myeloma and multiple mantle
cell lymphoma patients (Kane et al., 2006). A proposed mechanism
of bortezomib action is through the inhibition of IκB degradation
resulting in the abolition of NF-κB signaling (Tan and Waldmann,
2002).
Following the success in hematological cancers, the efficacy
of bortezomib therapy was investigated in solid tumors. Despite
promising pre-clinical data, bortezomib in combination with
temozolomide lacked efficacy in advanced refractory solid tumors
or melanoma patients in a phase II clinical trial (Clinicaltri-
als.gov identifier:NCT00512798) (Amiri et al., 2004). Similarly,
bortezomib in combination with other chemotherapeutic agents,
including paclitaxel and carboplatin, failed to alter NF-κB expres-
sion, showed limited clinical advantage and significant toxicity
in patients with advanced solid tumors (Croghan et al., 2010).
Various studies with bortezomib in the treatment of advanced
solid tumors, e.g., metastatic breast cancer (Yang et al., 2006a) and
urothelial cancer (Gomez-Abuin et al., 2007), have proven disap-
pointing. Numerous trials are currently being conducted to inves-
tigate the potential of bortezomib as an adjuvant to chemotherapy
in head and neck (Fury et al., 2012) and NSCLC (NCT01633645).
Bortezomib has previously shown a potential therapeutic ben-
efit in NSCLC patients and acts synergistically with cisplatin-
gemcitabine chemotherapy to constitute an active regimen in
advanced stage NSCLC patients (Voortman et al., 2007).
Other compounds that may be useful in increasing the sensitiv-
ity of cancers with constitutively active NF-κB to chemotherapeu-
tic drugs are herbs with anti-inflammatory properties including
the natural phenol curcumin and parthenolide which occurs in
the plant feverfew (Patel et al., 2000). Curcumin down-regulates
transcription factors important for cell growth and survival,
through modulation of the NF-κB and PI3K/AKT pathways
(Reuter et al., 2008). Curcumin alone or in combination with
chemotherapy is effective both in vitro and in vivo in a num-
ber of cancer types, including melanoma (Odot et al., 2004). The
side effects of curcumin appear to be limited, with high oral
doses being tolerated with minimal toxicity, although abdomi-
nal complaints have been reported (Lao et al., 2006; Epelbaum
et al., 2010). A phase I clinical trial of patients with multiple
myeloma showed that both curcumin alone or in combination
with bioperine, an alkaloid isolate from black pepper, decreased
NF-κB levels in peripheral blood mononuclear cells (PBMCs)
(NCT00113841). Similarly, in a phase II trial, curcumin decreased
NF-κB levels in PBMCs and possessed biological activity in
some patients with advanced pancreatic cancer (Dhillon et al.,
2008).
The aforementioned treatments are compounds which are not
targeted NF-κB therapies. Recently, attention has shifted to thera-
peutic agents which selectively target NF-κB. One such compound,
BMS-345541 selectively inhibits the catalytic subunit of IKK and
can suppress tumor growth in murine melanoma models (Yang
et al., 2006b). The cell permeable NBD (NEMO-binding domain)
peptide prevents NF-κB activation by binding NEMO, thereby
inhibiting NEMO-IκB complex formation (di Meglio et al., 2005).
In vitro studies demonstrate that NBD impairs the ability of NF-κB
to bind DNA, resulting in increased apoptosis in melanoma cells
(Ianaro et al., 2009). The NF-κB specific inhibitor DHMEQ, pre-
vents the nuclear translocation of the transcription factor, and has
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been shown to have anti-cancer effects in numerous different can-
cer subtypes (Umezawa and Chaicharoenpong, 2002; Umezawa,
2006). In addition, the testing of small molecule inhibitors to
neutralize NF-κB have identified potential new cancer therapeu-
tics, which require further investigation as to their clinical benefit
(Miller et al., 2010; Hwang et al., 2012; Mora et al., 2012). The
small molecule inhibitor, bindarit, an indazolic derivative, which
may down-regulate NF-κB through reduced phosphorylation of
IκBα and p65 (Zollo et al., 2012), has subsequently been shown
to modulate cancer cell proliferation and migration, impairing
metastatic disease in murine models of prostate and breast cancer,
through NF-κB and AKT inhibition (Zollo et al., 2012).
CONCLUSION
Aberrant NF-κB expression and regulation is involved in the
development of many different cancer types, where it medi-
ates the fine balance between cellular survival and death. The
importance of NF-κB activation in cancer cells is evidenced by
the widespread dysregulation of this transcription factor across
a wide spectrum of solid and hematological cancers. NF-κB
is also heavily implicated in the development of resistance to
platinum-based chemotherapies, such as cisplatin. Therefore,
NF-κB represents an attractive target for anti-cancer therapy par-
ticularly as an adjuvant to overcome resistance to platinum-based
chemotherapeutics.
The efficacy of targeted therapy is based on the oncogenic
dependence of cancer cells on mutated survival and apoptotic
pathways, such as NF-κB, which renders them more susceptible to
inhibitors. NF-κB is a master regulator of transcription and can
affect the expression of over 200 genes. Due to its overwhelm-
ing influence on cellular processes, care must be exercised when
blocking the NF-κB pathway to minimize off-target effects and
unwanted toxicities. Furthermore, as NF-κB is a converging point
for many intercellular pathways, it may be difficult to identify the
most effective pathway to target. Elucidation of cell specific path-
ways of NF-κB activation, as well as oncogene and apoptotic status,
could provide the means to effectively and specifically target frag-
ments of the NF-κB signaling network. Indeed it may prove more
beneficial to target a number of regulators of this pathway through
combinatorial therapeutic strategies. This may not only aid in
cancer diagnosis and prognosis but may also provide an effective
avenue to re-sensitize cancers to cisplatin based therapies.
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